Is There a Future for AKT Inhibitors in the Treatment of Cancer?

被引：36
|
作者：
Jansen, Valerie M. [1 ]
Mayer, Ingrid A. [1 ]
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Breast Canc Program, Nashville, TN 37232 USA
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 11期
关键词：
METASTATIC BREAST-CANCER; COMBINATION; THERAPY; DOMAIN;
D O I：
10.1158/1078-0432.CCR-16-0100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. (C) 2016 AACR.
引用
收藏
页码：2599 / 2601
页数：3
相关论文
共 50 条
  • [21] Aromatase inhibitors: Current indications and future prospects for treatment of postmenopausal breast cancer
    Arora, A
    Potter, JF
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (04) : 611 - 616
  • [22] Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
    Singh, Avineesh
    Patel, Preeti
    Patel, Vijay K.
    Jain, Deepak K.
    Veerasamy, Ravichandran
    Sharma, Prabodh C.
    Rajak, Harish
    CURRENT CANCER DRUG TARGETS, 2017, 17 (05) : 456 - 466
  • [23] Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
    Gasmi, Anis
    Roubaud, Guilhem
    Dariane, Charles
    Barret, Eric
    Beauval, Jean-Baptiste
    Brureau, Laurent
    Crehange, Gilles
    Fiard, Gaelle
    Fromont, Gaelle
    Gauthe, Mathieu
    Ruffion, Alain
    Renard-Penna, Raphaele
    Sargos, Paul
    Roupret, Morgan
    Ploussard, Guillaume
    Mathieu, Romain
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (01)
  • [24] Ceritinib increases sensitivity of AKT inhibitors to gastric cancer
    Wang, Jian
    Xu, Xiaqing
    Wang, Tingting
    Guo, Qingqu
    Dai, Xiaoyang
    Guo, Hongjie
    Zhang, Wenxin
    Cheng, Shuyuan
    Chen, Xi
    Ding, Ling
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 896
  • [25] Is there a future for prenyltransferase inhibitors in cancer therapy?
    Holstein, Sarah A.
    Hohl, Raymond J.
    CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (06) : 704 - 709
  • [26] Structural requirements of isoform-specific inhibitors of Akt: Implications in the development of effective cancer treatment strategies
    Adon, Tenzin
    Bhattacharya, Sanyukta
    Madhunapantula, SubbaRao, V
    Kumar, Honnavalli Yogish
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 287
  • [27] Akt: A NEW APPROACH FOR CANCER TREATMENT
    Thakur, Devendra Singh
    Kumar, Peeyush
    Kumar, Pramod
    Lal, Champa
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2010, 1 (08): : 29 - 36
  • [28] Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer
    Tandon, Nitin
    Luxami, Vijay
    Kant, Divya
    Tandon, Runjhun
    Paul, Kamaldeep
    RSC ADVANCES, 2021, 11 (41) : 25228 - 25257
  • [29] Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future
    DiPippo, Adam J.
    Patel, Neelam K.
    Barnett, Chad M.
    PHARMACOTHERAPY, 2016, 36 (06): : 652 - 667
  • [30] MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives
    Ram, Teja
    Singh, Ankit Kumar
    Kumar, Adarsh
    Singh, Harshwardhan
    Pathak, Prateek
    Grishina, Maria
    Khalilullah, Habibullah
    Jaremko, Mariusz
    Emwas, Abdul-Hamid
    Verma, Amita
    Kumar, Pradeep
    RSC MEDICINAL CHEMISTRY, 2023, 14 (10): : 1837 - 1857
12345